Dimeric Immunoconjugates for Simultaneous Dual-Payload Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional monomeric immunoconjugates face limitations in delivering multiple payloads to cancer cells simultaneously and effectively, leading to suboptimal pharmacokinetics, pharmacodynamics, and reduced Fc-receptor-mediated cytotoxicity, which can mask the Fc portion of the antibody and limit efficacy.
Innovation Solution
Dimeric immunoconjugates are developed, comprising two different payloads covalently crosslinked, allowing simultaneous delivery of two chemotherapeutics to cancer cells, enhancing synergistic antineoplastic activity through improved binding, endocytosis, and reduced reliance on Fc-receptor pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If monomeric immunoconjugates are used to deliver multiple payloads, then the structure becomes complex and Fc portion masking occurs, but simultaneous delivery of multiple payloads to cancer cells is required for synergistic activity
Solution Approach 1:
The patent divides the immunoconjugate into separate monomeric units, each carrying a single payload type, that can independently bind to cancer cells. This segmentation allows multiple different monomeric immunoconjugates to simultaneously target the same cancer cell without the structural complexity and Fc masking issues of attempting to combine multiple payloads in a single monomeric structure.
Solution Approach 2:
The patent combines multiple monomeric immunoconjugates in a therapeutic regimen to achieve simultaneous payload delivery. By administering multiple monomeric immunoconjugates that target the same cancer antigen, the system merges their effects to deliver different payloads to the same cancer cell, achieving synergistic antineoplastic activity without the structural problems of complex single-molecule designs.
2Reliability
If Fc-receptor pathways are relied upon for cytotoxicity, then antibody binding occurs, but the Fc portion is masked which limits efficacy
Solution Approach 1:
The patent extracts the cytotoxic function from the Fc-receptor pathway and places it directly in the payload components of the monomeric immunoconjugates. By using payloads that independently provide cytotoxic activity (such as cytotoxic drugs, radioisotopes, or toxin components), the system removes dependence on Fc-receptor mediation, thereby eliminating the Fc masking problem while maintaining reliable cytotoxicity.
Solution Approach 2:
The patent introduces alternative mediators of cytotoxicity in the form of specialized payloads that do not require Fc-receptor interaction. These payloads serve as intermediaries that directly deliver cytotoxic effects to cancer cells through antigen binding and internalization, bypassing the need for Fc-receptor pathways and avoiding the associated masking limitations.
3Adaptability or versatility
If multiple monomeric immunoconjugates are administered simultaneously, then payload diversity increases, but binding to the same cancer cell becomes unpredictable
Solution Approach 1:
The patent applies local quality by designing all monomeric immunoconjugates to target the same cancer-associated antigen. This ensures that while the payloads differ (providing diversity), the binding target is identical (providing reliability). By concentrating targeting specificity at the antigen-binding site while varying the payload components, the system achieves both payload diversity and reliable simultaneous delivery to the same cancer cell population.
Data Source
AI summary
This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.